ABOUT US

Our Vision

With a Vision of Making Quality Healthcare Affordable Through Drug Delivery Solutions Focusing On Patient Convenience and Adherence, ZIM’s value propositions is its ability to provide a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for development, manufacture and supply of innovative and differentiated generic pharmaceutical products to its customers globally.

OUR VALUES

Zeal

It is our only passion that will fuel our drive for excellence in product quality, affordability and marketability.

Challenging the Status Quo

Through relentless pursuit of excellence and encouraging innovation, which is the foundation of our success.

Integrity

Stringent adherence to the moral and ethical code of the company, including transparency, open communication channels and impartiality to make every member feel valued.

Skill Improvement

Continuous training and upgrading of employee skills and competencies of our team, to provide zero-defect, effective medicines to our patients.

Concern for Environment

Ensure judicious use and protection of the country’s resources by minimizing waste, thereby reducing the burden of cost of maintenance of such natural resources for future generations.

Empathy

Promote a sense of compassion among all members of the organization for the health and wellbeing of the common man, spurring each one to provide them with high quality affordable medicines.

Kindness

There is always a good and pleasant way of saying and doing things in all our interactions with colleagues, clients and others we meet at our work place. This is way we expect others to treat us.

Fairness

A fair treatment to all is the best way to create & retain our goodwill and the trust of our business associates and colleagues.

Zim Labs has technology backed solutions that enables catering across various therapeutic segments such as

Cardiovascular

Anti-infective

Gastrointestinal

Respiratory system

Nervous system

Musculoskeletal

Haematology system

Vitamins

Our innovative technology solutions include drug release profile modifications, solubility & stability enhancement, taste masking and dosage form transformation

VALUE ADDITION

We offer our customers a comprehensive range of value added solid dosage differentiated generic products in semi-finished and finished categories / formulations. These include granules, pellets (sustained, modified, extended release), taste masked powders, suspensions, tablets, capsules and their recently developed Oral Thin Films (OTF).

GEOGRAPHICAL EXPANSION

We use our proprietary knowledge, technology and manufacturing process expertise to bridge the technology gap in Tier III Pharmerging & ROW markets while assisting local players in various geographies to launch differentiated / combination generic products and compete.

HISTORY & PATH FORWARD
An overview of Zim Labs at a glance from its inception, current offerings to its path forward and the leadership behind the journey.

TECHNOLOGY MILESTONES
BUSINESS MILESTONES

TECHNOLOGY MILESTONES

1989

Establishment of Company and
first manufacturing site.

1993

WHO GMP Status and maiden
public issue.

2000

Pellets Technology
developed.

2005

Taste Masking
Technology Introduced.

2010

New Cephalosporin
Block Added.

2013

New Orally Disintegrating Strip (ODS)
Manufacturing Block Added.

2014

WHO-GMP Status for Orally Disintegrating Strip Mfg. Facility.

2015

EUGMP
Accreditation.

2018

EUGMP Audit Cleared Successfully by "EUGMP RE-ACCREDITED."

BUSINESS MILESTONES

2000

Leading supplier of pharmaceutical

products to government organizations through tenders from its WHO-GMP approved plant.

2001-2012

Developed Pellets, Granules and

Taste Masking Technology Platforms to change its focus to differentiated and higher margin products. Ventured into international markets in Middle East and North Africa (MENA). Established ‘Proof-of-Concept’ for Oral Thin Films and Nano-technology.

2012 - 2017

Funding from private

equity investor; focus on higher margin businesses; reduce deemed export and low margin government business. Upgraded its manufacturing facilities to EU-GMP standards; investment in team and processes. Invested in separate WHO-GMP approved OTF facility and commercialise OTF products. Entered into newer geographies like SEA, LatAm, CIS and Africa and grew Sri Lanka, Bangladesh and MENA. Focused on building a steady pipeline with dossier filings and own product registrations.

2018 - Future

ZIM LABORATORIES LIMITED GOT LISTED ON BOMBAY STOCK EXCHANGE

Continued focus in core PFI business through new geographies, new customer relationships and new product pipeline for its business partners. Growing its niche generic formulations business – through registration, marketing partnerships and continued launch of products in MENA, SE Asia, Latin America and CIS countries (as demonstrated in Sri Lanka). Launch of OTF (prescription and OTC products) as an alternate drug delivery platform across RoW / Emerging Markets and Regulated Markets. Invest in R&D to develop a pipeline of products with focus on developed markets and enhance capacity and flexibility by appropriate capex.

ZIM IN FOCUS

FOCUSED ON THE NDDS SEGMENT

Over time ZIM has created a long term sustainable advantage by focused on Novel Drug Delivery Solutions (NDDS) segment through continuous innovation and development of non-infringing technology platforms and supply of high quality products at competitive prices.

UNIQUE BUSINESS MODEL

ZIM leverages on its R&D capabilities and manufacturing skills to develop and supply differentiated generic products, in pre-formulation and formulation dosage forms, to business partners who need comprehensive support in product development, full manufacturing technical training, registration and sourcing of such differentiated products to boost their pipeline and compete.

INNOVATIVE AND DIFFERENTIATED PRODUCT PORTFOLIO

ZIM supplies a wide range of solid dosage differentiated products across various therapeutic segments. ZIM is a pioneer in the OTF technology in India and focussed on growing this platform in partnership with marketing companies and product originators.

EXTENSIVE R&D CAPABILITIES

ZIM has a state of the art R&D centre with a team of over 90 professionals. ZIM is now setting up a new R&D centre with team, equipment and capabilities targeted for developed markets.

TECHNOCRAT PROMOTER & PROFESSIONAL MANAGEMENT

TECHNOCART PROMOTER & PROFESSIONAL MANAGEMENT

The Company is led by an experienced technocrat who is supported by a well-qualified professional management team.

STATE OF THE ART MANUFACTURING SETUP

ZIM has three manufacturing blocks (General, Cephalosporin and OTF). ZIM general block is EU-GMP and WHO-GMP approved. Its Cephalosporin and OTF blocks are WHO-GMP approved. ZIM is amongst the few companies in India to receive WHO-GMP approval for its OTF facility.

MULTI-PRONGED GROWTH STRATEGY

ZIM’s multi-pronged growth strategy comprises of:
• Developing new technology platforms & differentiated generic products for itself and under license arrangement.
• Manufacturing and supply of finished and semi-finished formulations for RoW as well as emerging markets.
• Development of the Thin Film as an alternate delivery platform across all markets.

ROBUST FINANCIALS

The Company has improved its EBITDA Margins from 11% to 15% in last four years on account of continued focus on high margin businesses.

ACCREDITATIONS

Our facilities are accredited with respected certifications from authorized independent bodies, which are generally accepted worldwide as a mark of approval of the quality of the manufacturer’s operational capabilities. These accreditations are: